Well, there's, of course, for those patients who have significant hemolysis contributing to their symptoms, the various complement inhibitors available. And you know, depending on a patient ...

While existing C5 inhibitors have contributed to improved remission rates, many patients still experience residual disease activity due to incomplete complement inhibition. In addition to autoantibody ...

While existing C5 inhibitors have contributed to improved remission rates, many patients still experience residual disease activity due to incomplete complement inhibition. In addition to ...

Late-stage pipeline products can generate demand in the MG market and with diagnosed prevalent cases, will drive growth in ...

emphasizing the impact of complement inhibitors. June 19th 2024EP. 6: Eculizumab Impact on PNH Treatment Landscape and Unmet Needs in PNH Management Medical experts highlight unmet needs in the ...

A look at current therapies, clinical trial results, patient education, and emerging options for managing this progressive ...

AstraZeneca (AZ) has announced promising results from a late-stage study of its C5 complement inhibitor Ultomiris ...

The aHUS therapy landscape is on the cusp of disruption-with emerging oral drugs and biosimilars reshaping market dynamics ...

But the complement system is an oft-overlooked part of the immune system that could be exploited to create new therapies. It’s more than a decade since the first checkpoint inhibitor hit the ...